Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

PURPOSE: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. PATIENTS AND METHODS: In the double-blind, phase III BRIGHTER study (NCT02178956), patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manish A., Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Tebbutt, Niall C., Metges, Jean-Phillippe, Muro, Kei, Lee, Keun-Wook, Shen, Lin, Tjulandin, Sergei, Hays, John L., Starling, Naureen, Xu, Rui-Hua, Sturtz, Keren, Fontaine, Marilyn, Oh, Cindy, Brooks, Emily M., Xu, Bo, Li, Wei, Li, Chiang J., Borodyansky, Laura, Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433958/
https://www.ncbi.nlm.nih.gov/pubmed/35833783
http://dx.doi.org/10.1158/1078-0432.CCR-21-4021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433958/
https://www.ncbi.nlm.nih.gov/pubmed/35833783
http://dx.doi.org/10.1158/1078-0432.CCR-21-4021

Ejemplares similares